Article Text

Download PDFPDF

Oestrogen did not improve health related quality of life in postmenopausal women with hysterectomy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In postmenopausal women with prior hysterectomy, does conjugated equine oestrogen (CEE) improve health related quality of life (HRQOL)?

Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Gynaecology ★★★★★★☆ Endocrine ★★★★★☆☆


Embedded ImageDesign:

randomised placebo controlled trial (Women’s Health Initiative [WHI]).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded (patients, healthcare providers, {data collectors, and outcome assessors}).*

Embedded ImageFollow up period:

1 year.

Embedded ImageSetting:

{40 US clinical centres}.

Embedded ImagePatients:

10 739 postmenopausal women aged 50–79 years (mean age 64 y, 75% white) with prior hysterectomy. Exclusion criteria included probable survival <3 years and breast cancer. 17% of women had moderate to severe vasomotor symptoms.

Embedded ImageIntervention:

oral CEE 0.625 mg/day (n = 5310) or placebo (n = 5429).

Embedded ImageOutcomes:

HRQOL (RAND36, 36 items, 8 subscales, range for each subscale …

View Full Text


  • * See glossary

  • Information obtained from G. Anderson, WHI Investigators.

  • Information obtained from


  • For correspondence: Dr R L Brunner, University of Nevada School of Medicine, Reno, NV, USA. bbrunner{at}

  • Source of funding: National Heart, Lung, and Blood Institute.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd